Pay in 4 interest-free payments of $36.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Termination phase III development of TAK-875 (Fasiglifam) for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety
GSK343 significantly inhibited the invasion of EOC cells
6 µM but accelerates calcium deregulation and mitochondrial depolarization in glutamate-treated neurons
CHIR-124 potentiates the growth inhibitory effects of Irinotecan by abrogating the G2-M checkpoint and increasing tumor apoptosis in an orthotopic breast cancer xenograft model
Solubility: DMSO: 100 mg/mL(108
HLI 373 dihydrochloride Catalog No.:M8040-10 Termination phase III development ofHLI 373 is an inhibitor of Hdm2 ubiquitin ligase (E3) that blocks Hdm2 mediated ubiquitylation and proteasomal degradation of p53. HLI 373 induces apoptosis in several tumor cell lines that express wild type p53 such as LOX IMVI, A549, HT1080 and U2OS. Product information CAS Number: 1782531 99 0 Molecular Weight: 414. 33 Formula: C18H25Cl2N5O2 Chemical Name: 5 ((3 (dimethylamino)propyl)amino) 3, 10 dimethylpyrimido[4, 5 b]quinoline 2, 4(3H, 10H)
US$ 450.00
US$ 120.00
US$ 65.00
US$ 270.00
US$ 175.00
US$ 65.00
US$ 170.00
US$ 12.00
US$ 29.95